NO20045343L - Ny kombinasjon for behandling av luftveisforstyrrelser - Google Patents

Ny kombinasjon for behandling av luftveisforstyrrelser

Info

Publication number
NO20045343L
NO20045343L NO20045343A NO20045343A NO20045343L NO 20045343 L NO20045343 L NO 20045343L NO 20045343 A NO20045343 A NO 20045343A NO 20045343 A NO20045343 A NO 20045343A NO 20045343 L NO20045343 L NO 20045343L
Authority
NO
Norway
Prior art keywords
treatment
respiratory disorders
new combination
respiratory
combination
Prior art date
Application number
NO20045343A
Other languages
English (en)
Norwegian (no)
Inventor
Stefan Postius
Wolfgang-Alexander Simon
Guido Hanauer
Wolfgang Kromer
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of NO20045343L publication Critical patent/NO20045343L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20045343A 2002-05-07 2004-12-06 Ny kombinasjon for behandling av luftveisforstyrrelser NO20045343L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02010305 2002-05-07
PCT/EP2003/004653 WO2003094967A2 (en) 2002-05-07 2003-05-03 New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders

Publications (1)

Publication Number Publication Date
NO20045343L true NO20045343L (no) 2004-12-06

Family

ID=29414673

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045343A NO20045343L (no) 2002-05-07 2004-12-06 Ny kombinasjon for behandling av luftveisforstyrrelser

Country Status (17)

Country Link
US (1) US20050222193A1 (sr)
EP (1) EP1506016A2 (sr)
JP (1) JP2005528418A (sr)
KR (1) KR20050007476A (sr)
CN (1) CN1652822A (sr)
AU (1) AU2003227710A1 (sr)
BR (1) BR0309808A (sr)
CA (1) CA2484272A1 (sr)
EA (1) EA200401454A1 (sr)
HR (1) HRP20041160A2 (sr)
IL (1) IL164755A0 (sr)
MX (1) MXPA04011018A (sr)
NO (1) NO20045343L (sr)
PL (1) PL373287A1 (sr)
RS (1) RS95304A (sr)
WO (1) WO2003094967A2 (sr)
ZA (1) ZA200407896B (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043614A2 (en) * 2001-11-19 2003-05-30 Altana Pharma Ag Reversible proton pump inhibitors for the treatment of airway disorders
SE0303451D0 (sv) * 2003-12-18 2003-12-18 Astrazeneca Ab New compounds
EP1761157A1 (en) * 2004-04-30 2007-03-14 ALTANA Pharma AG Method of classifying gerd
AU2005291302A1 (en) * 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient
ES2677668T3 (es) 2010-11-16 2018-08-06 Texas Heart Institute Agonistas que mejoran la unión de células que expresan integrina a receptores de integrina
KR101873530B1 (ko) * 2012-04-10 2018-07-02 삼성전자주식회사 모바일 기기, 모바일 기기의 입력 처리 방법, 및 모바일 기기를 이용한 전자 결제 방법
JO3737B1 (ar) * 2015-07-21 2021-01-31 Athenex Therapeutics Ltd تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8621425D0 (en) * 1986-09-05 1986-10-15 Smith Kline French Lab Compounds
CZ290266B6 (cs) * 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
DE19541689A1 (de) * 1994-11-14 1996-05-15 Byk Gulden Lomberg Chem Fab Kombinationsarzneimittel
NZ298853A (en) * 1995-01-27 1998-07-28 Rhone Poulenc Rorer Ltd 5-[2-cyano-phenoxy]-2-phenyl-acetic acid derivatives
ATE301457T1 (de) * 1995-06-12 2005-08-15 Searle & Co Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
US5840917A (en) * 1995-09-26 1998-11-24 Takeda Chemical Industries, Ltd. Phosphorylamides, their preparation and use
US6380222B2 (en) * 1996-10-11 2002-04-30 Astrazeneca Ab Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
SE9603725D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New teatment
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
ES2232015T3 (es) * 1997-07-25 2005-05-16 Altana Pharma Ag Inhibidor de las bombas de protones en combinacion terapeutica con sustancias antibacterianas.
US6060472A (en) * 1998-04-06 2000-05-09 Apotex Inc. Thiadiazole compounds useful as inhibitors of H+ /K+ atpase
CA2341488A1 (en) * 1998-08-26 2000-03-09 Smithkline Beecham Corporation Therapies for treating pulmonary diseases
WO2000017200A1 (en) * 1998-09-23 2000-03-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahydropyridoethers
GB9911017D0 (en) * 1999-05-13 1999-07-14 Zeneca Ltd Pharmaceutical compositions
JP2003528878A (ja) * 2000-03-29 2003-09-30 アルタナ ファルマ アクチエンゲゼルシャフト イミダゾピリジン誘導体のプロドラッグ
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
US6528527B2 (en) * 2000-11-07 2003-03-04 Merck & Co., Inc. Method of treatment with a combination of a PDE4 inhibitor and a leukotriene antagonist
WO2003043614A2 (en) * 2001-11-19 2003-05-30 Altana Pharma Ag Reversible proton pump inhibitors for the treatment of airway disorders

Also Published As

Publication number Publication date
IL164755A0 (en) 2005-12-18
WO2003094967A2 (en) 2003-11-20
WO2003094967A3 (en) 2004-04-01
CA2484272A1 (en) 2003-11-20
MXPA04011018A (es) 2005-01-25
ZA200407896B (en) 2006-06-28
EA200401454A1 (ru) 2005-06-30
AU2003227710A1 (en) 2003-11-11
CN1652822A (zh) 2005-08-10
JP2005528418A (ja) 2005-09-22
PL373287A1 (en) 2005-08-22
RS95304A (sr) 2006-12-15
HRP20041160A2 (en) 2005-08-31
US20050222193A1 (en) 2005-10-06
BR0309808A (pt) 2005-03-01
KR20050007476A (ko) 2005-01-18
EP1506016A2 (en) 2005-02-16

Similar Documents

Publication Publication Date Title
NO20071240L (no) Terapeutiske anvendelser av RTP801 inhibitorer
DK1809280T3 (da) Mitotiske kinesininhibitorer og fremgangsmåder til anvendelse deraf
MY151032A (en) Treatment of tnf? related disorders
CY1118171T1 (el) Θεραπευτικη αντιμετωπιση της φαiνυλκετονουρiας me βη4
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
ATE408601T1 (de) Fredericamycin-derivate
DK1651161T3 (da) Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
DK1768490T3 (da) Systemer og fremgangsmåder til ex-vivo-organpleje
NO20034056D0 (no) Proliferative sykdommer
IS8071A (is) Aðferð við meðhöndlun á hnútahersli, fitudreyra og tengdum ástands tegundum og lyfjafræðilegum samsetningum
ATE256672T1 (de) 4,5-diaryl-3(2h)-furanon derivate als cyclooxygenase-2 inhibitoren
WO2005044199A3 (en) Combination of proton pump inhibitor and sleep aid
NO20075764L (no) Kombinert anvendelse av prostaglandinforbindelse og protonpumpeinhibitor til behandling av forstyrrelser i mage- og tarmkanalen
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
DE60329326D1 (de) Tace inhibitoren
ATE415961T1 (de) Therapeutische verwendung von mitgliedern der n,n-dicylcohexyl-2-hydroxy-7,7- dimethylbicycloä2.2.1ühept-1- ylmethanesulphonamide-familie
NO20073104L (no) Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
MXPA04011018A (es) Nueva combinacion de inhibidores reversibles de la bomba de protones y productos terapueticos para tratar trastornos de las vias respiratorias.
CY1110368T1 (el) Συνεργιστικος συνδυασμος ο οποιος περιλαμβανει ροφλουμιλαστη και (r,r)-φορμοτερολη
NO20073610L (no) Nye substituerte tiofenpyrimidinonderivater som inhibitorer for 17 β-hydroksysteroiddehydrogenase
NO20045344L (no) Kombinasjon for behandling av luftveisforstyrrelser
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
ATE410235T1 (de) Behandlung von ballastwasser

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104